Bezlotoxumab: Could This be the Answer for Clostridium difficile Recurrence?

  title={Bezlotoxumab: Could This be the Answer for Clostridium difficile Recurrence?},
  author={R. Chapin and Tiffany Lee and Christopher M McCoy and C. D. Alonso and M. Mahoney},
  journal={Annals of Pharmacotherapy},
  pages={804 - 810}
Objective: To review the pharmacology, pharmacokinetics, efficacy, safety, and place in therapy of bezlotoxumab (BEZ), a novel monoclonal antibody against Clostridium difficile toxin B. Data Sources: A PubMed search was conducted for data between 1946 and April 2017 using MeSH terms bezlotoxumab, MK-6072, or MDX-1388 alone and the terms Clostridium difficile combined with monoclonal antibody or antitoxin. Study Selection and Data Extraction: The literature search was limited to English-language… Expand
Bezlotoxumab for the prevention of Clostridium difficile infection: a review of current evidence and safety profile
Actoxumab + bezlotoxumab combination: what promise for Clostridium difficile treatment?
Update of treatment algorithms for Clostridium difficile infection.
  • R. Ooijevaar, Y. V. van Beurden, +5 authors E. Kuijper
  • Medicine
  • Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
  • 2018
Human C. difficile toxin–specific memory B cell repertoires encode poorly neutralizing antibodies


Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection
Mechanisms of Protection against Clostridium difficile Infection by the Monoclonal Antitoxin Antibodies Actoxumab and Bezlotoxumab
A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity.
Fidaxomicin versus vancomycin for Clostridium difficile infection.
Antibodies to Toxin B Are Protective Against Clostridium difficile Infection Recurrence.
Efficacy of Secondary Prophylaxis With Vancomycin for Preventing Recurrent Clostridium difficile Infections